Vaxart (VXRT) Projected to Announce Quarterly Earnings on Thursday

Vaxart (OTCMKTS:VXRT) will likely be posting its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $26.2120 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:30 PM ET.

Vaxart (OTCMKTS:VXRT) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, meeting the consensus estimate of $0.02. The business had revenue of $39.23 million for the quarter, compared to the consensus estimate of $50.50 million. Vaxart had a return on equity of 61.43% and a net margin of 14.51%. On average, analysts expect Vaxart to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vaxart Stock Performance

Shares of VXRT stock opened at $0.60 on Wednesday. Vaxart has a fifty-two week low of $0.30 and a fifty-two week high of $0.84. The firm has a market capitalization of $145.70 million, a PE ratio of 4.00 and a beta of 1.10. The stock’s 50-day simple moving average is $0.56 and its 200-day simple moving average is $0.63.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Vaxart to a “hold” rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall Wace LLP purchased a new position in shares of Vaxart during the 2nd quarter valued at about $794,000. Jones Financial Companies Lllp lifted its holdings in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Vaxart in the first quarter worth about $31,000. Creative Planning purchased a new stake in shares of Vaxart in the second quarter worth about $33,000. Finally, Invesco Ltd. boosted its stake in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after buying an additional 70,568 shares during the last quarter. 18.05% of the stock is currently owned by institutional investors and hedge funds.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.